Futura Medical PLC (AIM:FUM, OTC:FAMDF), a specialist in sexual health products, has extended its exclusive licensing agreement with distributor Cooper Consumer Health.
Effective until January 2029, the new agreement grants Cooper exclusive rights to commercialise Eroxon, Futura's gel-based erectile dysfunction (ED) treatment, in the European Economic Area, the United Kingdom and Switzerland. The original deal, signed in May 2022, was set to run for an initial five-year period.
Eroxon is notable as the first pan-European topical ED treatment available without a prescription. Its initial launches began last March in the UK and Belgium, with plans for further expansion across Europe in 2024, targeting major markets such as Italy, Spain, France and Germany.
Under the terms of the extended agreement, Futura remains the legal manufacturer and is responsible for supplying Eroxon via third-party contract manufacturers.
"The award-winning launch of Eroxon was a key milestone in our partnership with Cooper and the success of our collaboration makes this extension an easy decision for both parties," said Futura chief executive James Barder.
"We are committed to providing treatment to those suffering from ED and as such we continue the commercial roll-out of Eroxon across the world."